Cargando…
A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457768/ https://www.ncbi.nlm.nih.gov/pubmed/37631860 http://dx.doi.org/10.3390/vaccines11081291 |
_version_ | 1785097003861016576 |
---|---|
author | Liu, Wei Jiang, Peizhao Song, Tao Yang, Keli Yuan, Fangyan Gao, Ting Liu, Zewen Li, Chang Guo, Rui Xiao, Shaobo Tian, Yongxiang Zhou, Danna |
author_facet | Liu, Wei Jiang, Peizhao Song, Tao Yang, Keli Yuan, Fangyan Gao, Ting Liu, Zewen Li, Chang Guo, Rui Xiao, Shaobo Tian, Yongxiang Zhou, Danna |
author_sort | Liu, Wei |
collection | PubMed |
description | Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industry. Cellular immunity plays a key role in the prevention and control of porcine enzootic pneumonia. Therefore, the development of a more efficient vaccine that confers a strong immunity against M. hyopneumoniae is necessary. In this study, a multi-antigen chimera (L9m6) was constructed by combining the heat-labile enterotoxin B subunit (LTB) with three antigens of M. hyopneumoniae (P97R1, mhp390, and P46), and its immunogenic and antigenic properties were assessed in a murine model. In addition, we compared the effect of individual administration and multiple-fusion of these antigens. The chimeric multi-fusion vaccine induced significant cellular immune responses and high production of IgG and IgM antibodies against M. hyopneumoniae. Collectively, our data suggested that rL9m6 chimera exhibits potential as a viable vaccine candidate for the prevention and control of porcine enzootic pneumonia. |
format | Online Article Text |
id | pubmed-10457768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104577682023-08-27 A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice Liu, Wei Jiang, Peizhao Song, Tao Yang, Keli Yuan, Fangyan Gao, Ting Liu, Zewen Li, Chang Guo, Rui Xiao, Shaobo Tian, Yongxiang Zhou, Danna Vaccines (Basel) Article Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industry. Cellular immunity plays a key role in the prevention and control of porcine enzootic pneumonia. Therefore, the development of a more efficient vaccine that confers a strong immunity against M. hyopneumoniae is necessary. In this study, a multi-antigen chimera (L9m6) was constructed by combining the heat-labile enterotoxin B subunit (LTB) with three antigens of M. hyopneumoniae (P97R1, mhp390, and P46), and its immunogenic and antigenic properties were assessed in a murine model. In addition, we compared the effect of individual administration and multiple-fusion of these antigens. The chimeric multi-fusion vaccine induced significant cellular immune responses and high production of IgG and IgM antibodies against M. hyopneumoniae. Collectively, our data suggested that rL9m6 chimera exhibits potential as a viable vaccine candidate for the prevention and control of porcine enzootic pneumonia. MDPI 2023-07-28 /pmc/articles/PMC10457768/ /pubmed/37631860 http://dx.doi.org/10.3390/vaccines11081291 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Wei Jiang, Peizhao Song, Tao Yang, Keli Yuan, Fangyan Gao, Ting Liu, Zewen Li, Chang Guo, Rui Xiao, Shaobo Tian, Yongxiang Zhou, Danna A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title | A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title_full | A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title_fullStr | A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title_full_unstemmed | A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title_short | A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice |
title_sort | recombinant chimera vaccine composed of ltb and mycoplasma hyopneumoniae antigens p97r1, mhp390 and p46 elicits cellular immunologic response in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457768/ https://www.ncbi.nlm.nih.gov/pubmed/37631860 http://dx.doi.org/10.3390/vaccines11081291 |
work_keys_str_mv | AT liuwei arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT jiangpeizhao arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT songtao arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT yangkeli arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT yuanfangyan arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT gaoting arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT liuzewen arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT lichang arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT guorui arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT xiaoshaobo arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT tianyongxiang arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT zhoudanna arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT liuwei recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT jiangpeizhao recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT songtao recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT yangkeli recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT yuanfangyan recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT gaoting recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT liuzewen recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT lichang recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT guorui recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT xiaoshaobo recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT tianyongxiang recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice AT zhoudanna recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice |